Results 81 to 90 of about 284,051 (203)

The power of many: when genetics met yeasts and high‐throughput

Biological Reviews, Volume 101, Issue 4, Page 1662-1682, August 2026.
ABSTRACT In recent years, complex technological capabilities have evolved, driven by the need to solve complex and integrative biological questions through global analyses. New equipment allows the scaling up and automation of processes which previously were carried out on a very limited scale.
Víctor A. Tallada, Víctor Carranco
wiley   +1 more source

ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro‐Inflammatory Arachidonic Acid Metabolism and ALP Secretion

Immunity, Inflammation and Disease, Volume 14, Issue 8, August 2026.
ABSTRACT Background Asialoglycoprotein receptor 1 (ASGR1), a hepatocyte‐specific receptor, represents a potential therapeutic target for hypercholesterolemia. However, liver safety risks of ASGR1‐targeted therapies remain poorly characterized. This study aims to investigate the impact of ASGR1 deficency on liver fibrosis and its underlying mechanisms ...
Hui Zhu, Xin‐ping Huang, Kai You, Yan Chen, Peng‐hui Li, Jia‐wang Tao, Xiao‐rui Yu, Jie‐hui Xu, Guo‐sheng Xu, Yin‐xiong Li   +9 more
wiley   +1 more source

Patients' Attitudes Toward Detection of Heterozygous Familial Hypercholesterolemia

, 1997
BACKGROUND: Molecular biology has improved the diagnostic abilities of physicians and enabled them to identify apparently healthy persons with a high risk of genetic disease. OBJECTIVE: To examine the attitudes toward detection of disease and the present
Andersen, Lone K., Faergeman, Ole, Juul, Svend, Jensen, Henrik K.   +3 more
core   +1 more source

A Scoping Review of Electronic Health Records–Based Screening Algorithms for Familial Hypercholesterolemia [PDF]

BackgroundFamilial hypercholesterolemia (FH) is a common genetic disorder that is strongly associated with premature cardiovascular disease. Effective diagnosis and appropriate treatment of FH can reduce cardiovascular disease risk; however, FH is ...
Khoury, Muin J., Otchere, Baffour, Osei, Jeffery, Coronado, Fatima, Akyea, Ralph K., Bonful, Gracelove, Razavi, Alexander C., Akoto, Natalie, Kolor, Katherine, Mensah, George A., Sperling, Laurence, Moonesinghe, Ramal, Qureshi, Nadeem   +12 more
core   +1 more source

Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method

Practical Laboratory Medicine, 2015
Objectives: It is well known that familial hypercholesterolemia (FH) is a common inherited disorder that can markedly elevate the level of plasma LDL cholesterol.
Hayato Tada, Masa-aki Kawashiri, Atsushi Nohara, Akihiro Inazu, Hiroshi Mabuchi, Masakazu Yamagishi, Kenshi Hayashi   +6 more
doaj   +1 more source

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia [PDF]

, 1999
Background The aortic valve dysfunction of patients with homozygous familial hypercholesterolemia (FH) suggests that hypercholesterolemia affects not only coronary arteries, but also the aortic valve.
Yutani, Chikao, Miyatake, Kunio, Tsushima, Motoo, Yamamura, Taku, Beppu, Shintarou, Yamamoto, Akira, Kawaguchi, Akito   +6 more
core   +1 more source

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

, 2021
Background: The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of ...
Borghi C, Biasucci G, EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)   +2 more
core   +1 more source

Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention

International Journal of the Cardiovascular Academy
Hypercholesterolemia, a major contributor to atherosclerotic cardiovascular disease, remains inadequately controlled despite widespread statin use, particularly in patients with familial hypercholesterolemia or statin intolerance.
Agung Cendekia Putra Nusantara, Ariella Diandihati Rapsanjani, Ikhwan Handirosiyanto, Tara Mandiricha, Aisyah Silvia Gaffar   +4 more
doaj   +1 more source

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

Lipids in Health and Disease, 2017
Background Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal
Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, Mariko Harada-Shiba, Yasushi Ishigaki, Kimimasa Tobita, Yumiko Kawabata, Asuka Ozaki, Marie T. Baccara-Dinet, Masataka Sata   +9 more
doaj   +1 more source

Family heterozygous hypercholesterolemia: a case report

, 2019
Іntroduction: Familial hypercholesterolemia (FH) is an autosomal dominant disorder, caused by the defect of the gene, encoding the structure and function of the receptor for the apoprotein B/E. Patients with FH are predisposed to premature development of
Ждан, Вячеслав Миколайович, Бабаніна, Марина Юріївна, Babanina, M. Yu., Kitura, O. Ye., Кітура, Оксана Євгенівна, Zhdan, V. M., Kitura, Ye. M., Ткаченко, Максим Васильович, Tkachenko, M. V., Кітура, Євдокія Михайлівна   +9 more
core   +1 more source